CLASS II ONGOING Drug recall · Reported 2 Sep 2026 · FDA Enforcement Report

Levothyroxine Sodium Tablets, USP, 50 mcg 05 mg) recalled

Accord Healthcare is recalling Levothyroxine Sodium Tablets, USP, 50 mcg 05 mg), distributed nationwide in the US. The recall was initiated on 6 Aug 2026 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: D2401834, D2401982, Exp. Date 08/31/2026; D2402584, D2402585, D2402586, D2402588, D2402587, D2402589, Exp Date. 11/30/2026.
NDC16729-447, 16729-458, 16729-448, 16729-449, 16729-451, 16729-450
UPC0316729447157, 0316729449151, 0316729452151, 0316729454155, 0316729453158, 0316729448154
Quantity recalledN/A

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0776-2026
FDA event ID
99584
Recalling firm
Accord Healthcare, Raleigh, NC
Manufacturer
Accord Healthcare Inc.
Classification
Class II
Status
Ongoing
Recall initiated
6 Aug 2026
FDA classified
21 Aug 2026
Reported
2 Sep 2026
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

6 Aug 2026Recall initiated by company
21 Aug 2026Classified by FDA+15 days
2 Sep 2026Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-448-17.

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Is Levothyroxine Sodium Tablets, USP, 50 mcg 05 mg) recalled?

Yes. Accord Healthcare recalled Levothyroxine Sodium Tablets, USP, 50 mcg 05 mg) on 6 Aug 2026. The recall is Class II and its status is Ongoing. Recall number D-0776-2026.

Why was it recalled?

Subpotent Drug

Which lots are affected?

Lot #: D2401834, D2401982, Exp. Date 08/31/2026; D2402584, D2402585, D2402586, D2402588, D2402587, D2402589, Exp Date. 11/30/2026.

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Accord Healthcare

All 106

Other Levothyroxine recalls

All 114